KLH 2109Alternative Names: KLH-2109; OBE-2109
Latest Information Update: 14 Oct 2016
At a glance
- Originator Kissei Pharmaceutical
- Developer Kissei Pharmaceutical; ObsEva
- Class Antihormones
- Mechanism of Action LHRH receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Endometriosis; Uterine leiomyoma